沙库巴曲缬沙坦在心房颤动中的研究现状

doi:10.3969/j.issn.1004-583X.2025.05.015

摘要/Abstract

摘要：

心房颤动是临床上常见的心律失常之一,有效的治疗和预防其潜在的致心脑血管疾病的风险,一直是临床上研究的热点。沙库巴曲缬沙坦作为一种血管紧张素受体脑啡肽酶抑制剂,在治疗心房颤动方面的优势逐渐显现。充分的探讨沙库巴曲缬沙坦在心房颤动治疗中的潜在机制及其临床应用前景,将为心房颤动的治疗提供新思路。

中图分类号:

马亚敏, 耿涛. 沙库巴曲缬沙坦在心房颤动中的研究现状[J]. 临床荟萃, 2025, 40(5): 463-467.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2025.05.015

https://lchc.magtechjournal.com/CN/Y2025/V40/I5/463

参考文献 41

[1]	Li X, Zuo C, Chen C, et al. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study[J]. Int J Cardiol, 2023, 371(10):244-25.
[2]	曹馨瑞, 严思敏, 姚惠敏, 等. 沙库巴曲缬沙坦在心律失常治疗中的研究进展[J]. 中南药学, 2023, 21(3):726-730.
[3]	Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge[J]. Int J Stroke, 2021, 16(2):217-221.
[4]	Chen M, Li C, Liao P, et al. Epidemiology, management and outcomes of atrial fibrillation among 30 million medicare subjects of Shanghai, China from 2015 to 2020[J]. Lancet Reg Health West Pac, 2022,23:100470.
[5]	von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor lcz696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy[J]. Circ Heart Fail, 2015, 8(1):71-78. doi: 10.1161/CIRCHEARTFAILURE.114.001785 pmid: 25362207
[6]	Li Q, Fang Y, Peng DW, et al. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats[J]. Eur J Pharmacol, 2023, 952:175754.
[7]	Iwamiya S, Ihara K, Furukawa T, et al. Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice[J]. Front Cardiovasc Med, 2024, 11:1341601.
[8]	Suo Y, Yuan M, Li H, et al. Sacubitril/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice[J]. Front Pharmacol, 2019, 10:1285. doi: 10.3389/fphar.2019.01285 pmid: 31736759
[9]	Moon MG, Hwang IC, Lee HJ, et al. Reverse remodeling assessed by leftatrial and ventricular strain reflectstreatment response to sacubitril/valsartan[J]. JACC Cardiovasc Imaging, 2022, 15(9):1525-1541.
[10]	庞志华, 赵伟, 田留, 等. 沙库巴曲缬沙坦对心肌梗死后心力衰竭大鼠的心脏保护机制探讨[J]. 天津医药, 2022, 50(11):1171-1176.
[11]	Guo YH, Yang YQ. Atrial fibrillation: Focus on myocardial connexins and gap junctions[J]. Biology (Basel), 2022, 11(4):489.
[12]	孙昌民, 钟江华. NLRP3炎症小体在心房颤动中的作用机制[J]. 中国心血管病研究, 2024, 22(4):375-380.
[13]	Ajoolabady A, Nattel S, Lip GYH, et al. Inflammasome signaling in atrial fibrillation: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 79(23):2349-2366. doi: 10.1016/j.jacc.2022.03.379 pmid: 35680186
[14]	Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death[J]. Cell Mol Immunol, 2021, 18(9):2114-2127. doi: 10.1038/s41423-021-00740-6 pmid: 34321623
[15]	Li X, Zhu Q, Wang Q, et al. Protection of Sacubitril/valsartan against pathological cardiac remodeling by inhibiting the NLRP3 inflammasome after relief of pressure overload in mice[J]. Cardiovasc Drugs Ther, 2020, 34(5):629-640. doi: 10.1007/s10557-020-06995-x pmid: 32444995
[16]	De Vecchis R, Paccone A, Di Maio M. Upstream therapy for atrial fibrillation prevention: The role of sacubitril/valsartan[J]. Cardiol Res, 2020, 11(4):213-218.
[17]	De Vecchis R, Paccone A, Di Maio M. Favorable effects of sacubitril/valsartan on the peak atrial longitudinal strain in patients with chronic heart failure and a history of one or more episodes of atrial fibrillation: A retrospective cohort study[J]. J Clin Med Res, 2020, 12(2):100-107. doi: 10.14740/jocmr4076 pmid: 32095179
[18]	Badano LP, Kolias TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: A consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging[J]. Eur Heart J Cardiovasc Imaging, 2018, 19(6):591-600. doi: 10.1093/ehjci/jey042 pmid: 29596561
[19]	Hopman LHGA, Bhagirath P, Mulder MJ, et al. Left atrial sphericity in relation to atrial strain and strain rate in atrial fibrillation patients[J]. Int J Cardiovasc Imaging, 2023, 39(9):1753-1763.
[20]	Brás PG, Gonçalves AV, Branco LM, et al. Sacubitril/valsartan improves left atrial and ventricular strain and strain rate in patients with heart failure with reduced ejection fraction[J]. Life (Basel), 2023, 13(4):995.
[21]	成绩, 胡豪畅, 林少沂, 等. 沙库巴曲缬沙坦治疗心血管疾病临床应用研究进展[J]. 浙江医学, 2022, 44(4):441-446.
[22]	Cheng WH, Lugtu IC, Chang SL, et al. Effects of angiotensin receptor-neprilysin inhibitor in arrhythmogenicity following left atrial appendage closure in an animal model[J]. Cardiovasc Drugs Ther, 2021, 35(4):759-768.
[23]	Reilly SN, Jayaram R, Nahar K, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: Implications for the antiarrhythmic effect of statins[J]. Circulation, 2011, 124(10):1107-1117. doi: 10.1161/CIRCULATIONAHA.111.029223 pmid: 21844076
[24]	Artaç İ, Öˇgün M, Omar T, et al. The importance of nitric oxide and oxidative stress in atrial high-rate episodes in patients with cardiac devices[J]. Turk Kardiyol Dern Ars, 2024, 52(2):81-87. doi: 10.5543/tkda.2023.07433 pmid: 38465533
[25]	徐登月, 于立明, 王辉山. 氧化应激作用于房颤发病机制中的研究现状[J]. 中国临床药理学杂志, 2023, 39(4):583-587.
[26]	王思佳, 赵育洁, 王地, 等. 沙库巴曲/缬沙坦在快速型室性心律失常领域中的研究进展[J]. 中国循证心血管医学杂志, 2023, 15(1):120-122+126.
[27]	Wang Y, Zhou R, Lu C, et al. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: Meta-analysis[J]. J Am Heart Assoc, 2019, 8(13):e012272.
[28]	Chang PC, Wo HT, Lee HL, et al. Sacubitril/valsartan therapy ameliorates ventricular tachyarrhythmia inducibility in a rabbit myocardial infarction model[J]. J Card Fail, 2020, 26(6):527-537.
[29]	Ge Q, Zhao L, Ren XM, et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis[J]. Exp Biol Med (Maywood), 2019, 244(12):1028-1039. doi: 10.1177/1535370219861283 pmid: 31262190
[30]	Okutucu S, Fatihoglu SG, Sabanoglu C, et al. Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction[J]. Herz, 2021, 46(Suppl 1):69-74. doi: 10.1007/s00059-019-04872-4
[31]	Zhu T, Zhang W, Yang Q, et al. Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:1048077.
[32]	Russo V, Bottino R, Rago A, et al. The effect of sacubitril/valsartan on device detected arrhythmias and electrical parameters among dilated cardiomyopathy patients with reduced ejection fraction and implantable cardioverter defibrillator[J]. J Clin Med, 2020, 9(4):1111.
[33]	Guerra F, Pimpini L, Flori M, et al. Sacubitril/valsartan reduces atrial fibrillation and supraventricular arrhythmias in patients with HFrEF and remote monitoring: preliminary data from the SAVE THE RHYTHM[J]. Eur Heart J, 2020, 41(Supplement_2).
[34]	Abumayyaleh M, Demmer J, Krack C, et al. Incidence of atrial and ventricular arrhythmias in obese patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan[J]. Diabetes Obes Metab, 2023, 25(10):2999-3011.
[35]	Dong Y, Zhai Z, Wang J, et al. Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation[J]. Sci Rep, 2023, 13(1):3140. doi: 10.1038/s41598-023-30349-w pmid: 36823222
[36]	Chen Q, Chen Y, Qin F, et al. Effect of sacubitril-valsartan on restoration and maintenance of sinus rhythm in patients with persistent atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:870203.
[37]	毕龙飞, 刘瑶, 余丹, 等. 沙库巴曲缬沙坦治疗消融术后心房颤动的疗效及安全性的Meta分析[J]. 医学新知, 2024, 34(8):916-926.
[38]	Zang X, Zhao Z, Chen K, et al. Evaluation of the efficacy of sacubitril/valsartan on radiofrequency ablation in patients with hypertension and persistent atrial fibrillation[J]. Cardiovasc Drugs Ther, 2025, 39(1):97-106.
[39]	Yang L, Zhang M, Hao Z, et al. Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients[J]. ESC Heart Fail, 2022, 9(4):2428-2434. doi: 10.1002/ehf2.13937 pmid: 35437929
[40]	格日勒, 吴云, 郭欣君, 等. 芪苈强心胶囊联合沙库巴曲缬沙坦钠治疗非射血分数减低型心力衰竭的疗效[J]. 疑难病杂志, 2021, 20(7):653-657.
[41]	Wang R, Ye H, Ma L, et al. Effect of sacubitril/valsartan on reducing the risk of arrhythmia: A systematic review and meta-analysis of randomized controlled trials[J]. Front Cardiovasc Med, 2022, 9:890481.

沙库巴曲缬沙坦在心房颤动中的研究现状

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	李雯琳, 张志. 心房颤动患者左心耳形态结构和功能与左心耳血栓及心源性卒中的关系研究进展[J]. 临床荟萃, 2024, 39(2): 168-171.
[3]	朱春瑜, 林春艺, 翁兰, 杨洵杰, 董帝辉. 高功率短时程在持续性心房颤动改良BOXI术式中的有效性和安全性[J]. 临床荟萃, 2024, 39(10): 915-920.
[4]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[5]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[6]	马静红, 杨倩, 贾永建, 党懿. 心房颤动导管消融围术期不间断新型口服抗凝剂和不间断华法林抗凝导致心脏压塞风险的荟萃分析[J]. 临床荟萃, 2022, 37(9): 773-778.
[7]	张海福, 叶向晴, 陈者旭, 陈施鉴, 杨栋, 张邢炜. 适量运动对心房颤动患者预后的影响:系统综述与Meta分析[J]. 临床荟萃, 2022, 37(6): 485-489.
[8]	章敬水, 徐亚男, 王钧, 杨毅, 姜海兵, 唐龙, 王贤平, 邵名亮. 新发的不同类型心力衰竭合并心房颤动的临床特点和远期预后分析[J]. 临床荟萃, 2022, 37(6): 504-509.
[9]	李卫伟, 李亚男. 左房容积指数用于预测心房颤动患者射频消融后复发的meta分析[J]. 临床荟萃, 2022, 37(11): 965-968.
[10]	安景景, 王小娟, 邓爱云. 预激综合征伴心房颤动射频消融术后心房颤动复发率的meta分析[J]. 临床荟萃, 2022, 37(10): 899-904.
[11]	曹晶晶, 张英杰, 常丽娟. 心房颤动发病机制及相关生物标志物研究进展[J]. 临床荟萃, 2022, 37(10): 946-949.
[12]	赵美丽, 肖立远, 刘林, 康超, 张秋香. NT-proBNP、hs-CRP、LAD与慢性心力衰竭合并心房颤动的相关性[J]. 临床荟萃, 2021, 36(5): 412-415.
[13]	简郭进, 张斌. 沙库巴曲缬沙坦在心血管疾病中的研究进展[J]. 临床荟萃, 2021, 36(11): 1041-1045.
[14]	耿彦平，王立立，谷剑，齐鹏，陈淑霞. 抗凝治疗量表中文版效度及信度分析[J]. 临床荟萃, 2020, 35(9): 788-791.
[15]	贺玉琴1，刘永铭2，闫芳芳1. LCZ696治疗心力衰竭有效性与安全性meta分析[J]. 临床荟萃, 2020, 35(7): 581-588.